Status:
COMPLETED
Fetal Exposure to Cannabinoids: Exposure, Methylation and Neurodevelopmental Effects
Lead Sponsor:
University of Arkansas
Conditions:
Fetal Exposure Timing Unspecified
Eligibility:
FEMALE
18+ years
Brief Summary
Cannabis is a very popular drug for both recreational and medicinal use. An estimated 20% of adults in the United States report using cannabis in the past month, and this number continues to increase ...
Detailed Description
Cannabis is a very popular drug for both recreational and medicinal use. An estimated 20% of adults in the United States report using cannabis in the past month, and this number continues to increase ...
Eligibility Criteria
Inclusion
- Pregnant women
- Age 18 and older
- Must plan to give birth at UAMS
- Report regular (at least 3x per week) use of THC- and/or CBD-containing product anytime during pregnancy (for experimental groups). Women who discontinue use of marijuana and/or CBD during pregnancy will still be allowed in the study.
- Pregnant women who do not use THC or CBD will be enrolled as controls.
Exclusion
- Any other illicit drug use during pregnancy
- Plan to give birth anywhere other than UAMS
Key Trial Info
Start Date :
February 26 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2023
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT04422600
Start Date
February 26 2020
End Date
August 1 2023
Last Update
September 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States, 72205